We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate (JP015)

This study has been withdrawn prior to enrollment.
(Drug combination is no longer pursued)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01002183
First Posted: October 27, 2009
Last Update Posted: September 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Mahidol University
Thammasat University
Information provided by:
Jomaa Pharma GmbH
  Purpose
The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute Plasmodium falciparum malaria while retaining its excellent safety profile

Condition Intervention Phase
Malaria Drug: Fosmidomycin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria

Resource links provided by NLM:


Further study details as provided by Jomaa Pharma GmbH:

Primary Outcome Measures:
  • Efficacy of fosmidomycin and clindamycin/artesunate when co-administered to adults with acute uncomplicated P.f. malaria. [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • To determine the viability and infectivity of gametocytes induced by the co-administration of fosmidomycin with clindamycin or with clindamycin plus artesunate to adult subjects with acute uncomplicated Plasmodium falciparum malaria. [ Time Frame: 12 months ]

Estimated Enrollment: 40
Arms Assigned Interventions
No Intervention: single arm
Fos-clin/Arte
Drug: Fosmidomycin
450 mg capsules, every 12 hrs for 3 days

Detailed Description:
The scientific rationale for the use of this combination is to inhibit the ability of the parasite to synthesise isoprenoids, as precursors of many essential compounds including sterols, carotenoids and ubiquinones. This is effected through blockade of the non-mevalonate pathway by fosmidomycin as a potent inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase coupled with targeting of protein biosynthesis by azithromycin through binding to the 50S ribosomal subunit. This mode of action contrasts with the ability of the human host to utilise the mevalonate pathway for isoprenoid synthesis and accounts for the safety profiles of both drugs through the mechanism of selective toxicity. Moreover it affords protection against cross resistance with existing chemotherapeutic agents.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male and female subjects aged 15 to 55 years
  • body mass index ≥ 18.5kg/M2
  • uncomplicated P falciparum malaria with acute manifestations
  • asexual parasitaemia between 500uL and 100,000uL
  • ability to tolerate oral therapy
  • able to give informed signed consent

Exclusion Criteria:

  • signs of severe malaria, according to WHO criteria
  • body mass index ≤ 18.5kg/M2
  • pregnancy by history or by positive urine test
  • lactation
  • mixed plasmodial infection
  • concomitant disease masking assessment of response, including diabetes,
  • uncontrolled hypertension, heart failure, hepatic dysfunction (alanine-amino transferase >150 U/L), renal impairment (creatinine >125umol/L or 3mg/dl)
  • haemoglobin < 8g/dl
  • white cell count > 12000/uL
  • anti-malarial treatment within previous 28 days
  • symptomatic AIDS
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002183


Locations
Thailand
Mahidol University
Bangkok, Thailand, 10400
Sponsors and Collaborators
Jomaa Pharma GmbH
Mahidol University
Thammasat University
  More Information

Responsible Party: Dr David BA Hutchinson, Jomaa Pharma GmbH
ClinicalTrials.gov Identifier: NCT01002183     History of Changes
Other Study ID Numbers: JP015
First Submitted: October 26, 2009
First Posted: October 27, 2009
Last Update Posted: September 27, 2011
Last Verified: August 2010

Keywords provided by Jomaa Pharma GmbH:
Malaria
Plasmodium falciparum
acute uncomplicated

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Fosmidomycin
Fosfomycin
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action